BioInvent International AB (publ) (LON:0H22)
London · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 117.52M -42.1% |
| Revenue (ttm) | 17.34M +258.3% |
| Net Income | -26.69M |
| EPS | -0.41 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 23.45 |
| Day's Range | n/a |
| 52-Week Range | 19.46 - 38.83 |
| Beta | 0.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About LON:0H22
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin’s lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to t... [Read more]
Financial Performance
In 2025, LON:0H22's revenue was 226.50 million, an increase of 406.86% compared to the previous year's 44.69 million. Losses were -332.86 million, -22.48% less than in 2024.
Financial numbers in SEK Financial StatementsNews
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer
FDA Fast Track Designation granted for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of ovarian cancer. BI-1808 in combination with pembrolizumab demonstrated a 24% confirmed ORR an...
BioInvent International: BioInvent Publication in JECCR: Tailored Fc?R Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models
LUND, SE / ACCESS Newswire / July 28, 2026 / BioInvent International (STO:BINV)Preclinical proof-of-concept data support two distinct Fc?R-blockade strategies to enhance cancer antibody therapies a...
BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models
LUND, SE / ACCESS Newswire / July 28, 2026 / BioInvent International (STO:BINV) Preclinical proof-of-concept data support two distinct FcγR-blockade strategies to enhance cancer antibody therapies and...
BioInvent International: BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026
LUND, SE / ACCESS Newswire / July 17, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that ...
BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026
LUND, SE / ACCESS Newswire / July 17, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that its...
BioInvent International AB Transcript: KOL event
Key opinion leaders highlighted the strong efficacy and safety of BI-1206 and BI-1808 in lymphoma and CTCL, emphasizing their differentiated mechanisms and commercial potential. Both assets are advancing toward pivotal studies, with safety and convenience seen as major advantages for broad patient adoption.
BioInvent International AB Press release: KOL event
BioInvent International AB issued a press release on June 11, 2026, disclosing material business information to investors.
BioInvent International AB Slides: KOL event
BioInvent International AB has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
BioInvent International AB Transcript: Aktiedagarna 2026
Focus is on advancing two immuno-oncology programs, with BI-1808 in ovarian cancer showing strong efficacy and safety, and BI-1206 positioned for partnering. Financial strategy centers on partnerships and royalty monetization, with a cash runway into Q1 next year. Key milestones and pivotal study readiness are expected in the next 12–24 months.
BioInvent International AB Transcript: Jefferies Global Healthcare Conference 2026
Two first-in-class immuno-oncology programs showed strong efficacy and safety in ovarian cancer, T-cell lymphoma, and non-Hodgkin lymphoma, with pivotal studies and regulatory filings planned. Key data updates and comparative studies are expected in the coming year.
BioInvent International: BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
LUND, SE / ACCESS Newswire / June 1, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that i...
BioInvent International AB Transcript: KOL event
BI-1808, a first-in-class TNFR2-targeting antibody, shows promising efficacy and safety in heavily pretreated ovarian cancer, with a 24% response rate and 10.3 months median PFS. The asset's differentiated mechanism and favorable profile support its advancement into triplet combinations and pivotal trials.
BioInvent International AB Slides: KOL event
BioInvent International AB has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
BioInvent International AB Slides: Corporate presentation
BioInvent International AB has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
BioInvent International: BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026
LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that i...
BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026
LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, today announced that it w...
BioInvent International: BioInvent to Present Clinical Data on Fc?RIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence in Relapsed/Refractory NHL at EHA 2026
LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulato...
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026
LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory ...
BioInvent International: Resolutions at BioInvent's Annual General Meeting 2026
LUND, SE / ACCESS Newswire / April 29, 2026 / The Annual General Meeting (AGM) of BioInvent International AB (BioInvent) (Nasdaq Stockholm:BINV) resolved to elect Kate Hermans and Scott Zinober as ...
Resolutions at BioInvent's Annual General Meeting 2026
LUND, SE / ACCESS Newswire / April 29, 2026 / The Annual General Meeting (AGM) of BioInvent International AB (BioInvent) (Nasdaq Stockholm:BINV) resolved to elect Kate Hermans and Scott Zinober as new...
Resolutions at BioInvent's Annual General Meeting 2026
LUND, SE / ACCESS Newswire / April 29, 2026 / The Annual General Meeting (AGM) of BioInvent International AB (BioInvent) (Nasdaq Stockholm:BINV) resolved to elect Kate Hermans and Scott Zinober as new...
BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio
Events will feature expert perspectives on BI-1808 in ovarian cancer and T‑cell lymphomas, and BI-1206 for the treatment of NHL LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International AB...
BioInvent International AB: Interim Report January - March 2026
LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most adva...
BioInvent International AB Quarterly report: Q1 2026
BioInvent International AB has published its Q1 2026 quarterly earnings report on April 29, 2026.
BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting
BioInvent International (STO:BINV) - BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when com...